2.90

1.02% -0.03

Pre-market: 2.94 0.04 +1.38%

Altimmune Inc (ALT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Altimmune Inc stock is traded at $2.90, with a volume of 1.99M. It is down -1.02% in the last 24 hours and down -16.43% over the past month. Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Previous Close:

$2.93

Open:

$2.94

24h Volume:

1.99M

Relative Volume:

0.51

Market Cap:

$563.98M

Revenue:

$41,000

Net Income/Loss:

$-88.09M

P/E Ratio:

-2.856

EPS:

-1.0154

Net Cash Flow:

$-67.55M

1W Performance:

+1.75%

1M Performance:

-16.43%

6M Performance:

-39.71%

1Y Performance:

-49.74%

1-Day Range:

$2.88

$3.00

1-Week Range:

$2.72

$3.00

52-Week Range:

$2.56

$7.73

Altimmune Inc Stock (ALT) Company Profile

Name

Altimmune Inc

Sector

Healthcare (1106)

Industry

Biotechnology (618)

Phone

(240) 654-1450

Address

910 CLOPPER ROAD, GAITHERSBURG, MD

Employee

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

ALT's Discussions on Twitter

Compare ALT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALT Altimmune Inc	2.90	569.81M	41,000	-88.09M	-67.55M	-1.0154
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Upgrade	Goldman	Sell → Neutral
Mar-18-26	Initiated	Truist	Buy
Jan-28-26	Initiated	Barclays	Overweight
Jul-10-25	Resumed	Goldman	Sell
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy
Nov-12-24	Initiated	UBS	Buy
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral
Mar-22-23	Downgrade	Goldman	Buy → Neutral
Dec-01-22	Initiated	Goldman	Buy
Dec-29-21	Resumed	Jefferies	Buy
Jun-02-21	Initiated	H.C. Wainwright	Buy
Feb-11-21	Initiated	Guggenheim	Buy
Dec-14-20	Initiated	Jefferies	Buy
Nov-12-20	Reiterated	B. Riley Securities	Buy
Sep-25-20	Initiated	B. Riley FBR	Buy
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight
Jul-28-20	Initiated	JMP Securities	Mkt Outperform
Feb-24-20	Resumed	ROTH Capital	Buy
Jul-19-19	Initiated	ROTH Capital	Buy
Oct-09-17	Initiated	Piper Jaffray	Overweight

View All

Altimmune Inc Stock (ALT) Latest News

May 25, 2026

H.C. Wainwright cuts Altimmune stock price target on dilution - Investing.com India

May 19, 2026

H.C. Wainwright cuts Altimmune stock price target on dilution By Investing.com - Investing.com South Africa

May 19, 2026

H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo

May 19, 2026

Several Insiders Invested In Altimmune Flagging Positive News - simplywall.st

May 19, 2026

May 18, 2026

ALT Maintained by HC Wainwright & Co. -- Price Target Lowered to $20 - GuruFocus

May 18, 2026

H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $20 - Moomoo

May 18, 2026

Altimmune Price Target Cut to $20.00/Share From $25.00 by HC Wainwright & Co. - Moomoo

May 18, 2026

Altimmune Inc Price USD, ALT Price Live Charts, Market Cap & News - Bitget

May 18, 2026

May 16, 2026

ALT: Altimmune Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

May 16, 2026

May 15, 2026